| ObjectivesTo investigate the safety of Chinese medicine decoction for treatment of the non-dialysis patients of chronic kidney disease (CKD) stages3to5on the point of serum potassium.MethodsThis study was designed as a non-controlled observational study. We included non-dialysis patients of CKD stages3-5who insist to treated with Chinese medicine decoction and visiting the renal outpatient clinic of Guangdong Province Hospital of Traditional Chinese Medicine(TCM) during November2010and February2012. All the participants were given the health care education of CKD, in order to have a low potassium diet wash period. There was no restriction on prescriptions of both TCM and western medicine. We recorded the data of blood and urine tests, components of TCM prescription, Chinese patent medicine and western medicine prescription on the start, the fourth week, the eight week and endpoint. We established the database by EXCEL, and data were analyzed by SPSS18.0. All statistic tests used in this study did on two-sided test and the a=0.05. Chi-square test or Fisher’s exact test and repeated measures analysis of variance were used for single factor analysis, and logistic regression model was used for multivariate analysis to detect to the protective and risk factors of hyperkalemia.Result65patients were included,31male and34female, age during18to80(60.23±14.7) years old。We found that:1. Serum potassium showed a slight rising trend, but there was no significant difference (P>0.05);2. The basic serum potassium was much higher in the hyperkalemia group than the normokalemia group (P<0.05);3. There was no correlation between the change of serum potassium and the potassium of chinese medicine;4. Serum creatinine (B=l.325,OR=3.674) and combining drugs including ACE inhibitor, ARB,?locker, or spirolactone (B=2.063,OR=7.868) were the risk factors of rising potassium.ConclusionChinese Medicine as a treatment for non-dialysis patients of chronic kidney disease stages3to5is relatively safe and will not rise the serum potassium within normal basic serum potassium. But it should pay attention to the patients who have a high potassium level before treatment, and who take ACE inhibitor, ARB,? Rbs or spirolactone. We advise to monitor serum potassium frequently when treated with chinese medicine. For the limitation of the design, further studies of well design are needed. |
